Top-News
Biotechnologie USA

PTC Therapeutics Aktie

Aktie
WKN:  A1W0MW ISIN:  US69366J2006 US-Symbol:  PTCT
45,00 €
+0,80 €
+1,81%
12.12.24
Handeln Depot/Watchlist
Aktienanzahl *
-
Marktkapitalisierung *
-
Streubesitz
-6,51%
Index-Zugehörigkeit
-
IR-Website
zur Website

PTC Therapeutics News

02.12.24 - PR Newswire
PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program
PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program PR Newswire
27.11.24 - PR Newswire
PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million
PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million PR Newswire
26.11.24 - PR Newswire
PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients
PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS Patients PR Newswire
25.11.24 - PR Newswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
13.11.24 - PR Newswire
PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy
PTC Therapeutics Announces FDA Approval of AADC Deficiency Gene Therapy PR Newswire
07.11.24 - PR Newswire
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results PR Newswire
04.11.24 - PR Newswire
PTC Therapeutics to Participate at Upcoming Investor Conferences
PTC Therapeutics to Participate at Upcoming Investor Conferences PR Newswire
30.10.24 - PR Newswire
PTC Therapeutics Announces FDA Acceptance of Translarna™ NDA Resubmission
PTC Therapeutics Announces FDA Acceptance of Translarna™ NDA Resubmission PR Newswire
25.10.24 - PR Newswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
24.10.24 - PR Newswire
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2024 Financial Results
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2024 Financial Results PR Newswire
18.10.24 - PR Newswire
CHMP Maintains Negative Opinion on Translarna™ Reexamination
CHMP Maintains Negative Opinion on Translarna™ Reexamination PR Newswire
14.10.24 - PR Newswire
PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results
PTC Therapeutics Announces FDA Target Regulatory Action Date for Sepiapterin and Lancet Publication of Phase 3 Trial Results PR Newswire
08.10.24 - PR Newswire
PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program
PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program PR Newswire
01.10.24 - PR Newswire
PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients
PTC Therapeutics Announces FDA Acceptance for Filing of NDA for Sepiapterin for the Treatment of Pediatric and Adult Phenylketonuria Patients PR Newswire
26.09.24 - PR Newswire
FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program
FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program PR Newswire
12.09.24 - PR Newswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
28.08.24 - PR Newswire
PTC Therapeutics to Participate at Upcoming Investor Conferences
PTC Therapeutics to Participate at Upcoming Investor Conferences PR Newswire
09.08.24 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire
08.08.24 - PR Newswire
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results PR Newswire
01.08.24 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT PR Newswire

Newssuche

Videos

newspaper
13.12.24
TRADING Insights Webinar vom 12.12.24
Themen: Aktienmarkt-​Entwicklung, Soft-​Commodities, wie Baumwolle, Kakao, Orangensaft, aber auch die ... Mehr »